ACT price (change in ACT prices for children under 5 years)c · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
ACT market share (volume of ACTs purchased as a proportion of all antimalarials purchased; all age groups) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 2 participants
High
Use of older antimalarials (amodiaquine, sulphadoxine‐pyrimethamine; children under 5 years) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
Adverse effects (such as the number of people receiving ACTs who do not have malaria) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
Progression to oxygen therapy · people with confirmed COVID‐19
Favipiravir showed no clear difference in progression to oxygen therapy compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
The intervention may leads to lower overall survival (low certainty).
1 finding from 1 review
Intervention not reported
Toxic death · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
1 finding from 1 review
Intervention not reported
Adverse effects · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
1 finding from 1 review
Intervention not reported
Quality of life · patients with extensive SCLC who relapsed or progressed after first‐line chemotherapy
The intervention may leads to higher quality of life (low certainty).
1 finding from 1 review
Intervention not reported
RT60 (5 RCTs; 713 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
The intervention probably leads to lower RT60 (5 RCTs; 713 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
BEV_RT (1 RCT; 75 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
The intervention showed no clear difference in BEV_RT (1 RCT; 75 participants); GRADE not reported.
1 finding from 1 review
Intervention not reported
RT40 (4 RCTs; 930 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
The intervention may leads to lower RT40 (4 RCTs; 930 participants) (low certainty).
1 finding from 1 review
Intervention not reported
TMZ (3 RCTs, 538 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
The intervention may leads to lower TMZ (3 RCTs, 538 participants) (low certainty).
1 finding from 1 review
Intervention not reported
CRT (2 RCTs; 635 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
The intervention led to lower CRT (2 RCTs; 635 participants); GRADE not reported.
1 finding from 1 review
Intervention not reported
BEV_CRT (1 RCT; 73 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
The intervention led to lower BEV_CRT (1 RCT; 73 participants); GRADE not reported.
1 finding from 1 review
Depressive symptoms · Post‐TBI Depression
It is very uncertain whether CBT changes beck Depression Inventory (BDI); higher score means more depressed compared with supportive Psychotherapy (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with best supportive care (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes overall response rate compared with best supportive care (very low certainty).
1 finding from 1 review